BioSpace News Archive

Daiichi Sankyo Company, Limited and AstraZeneca’s ENHERTU® has been granted Orphan Drug Designation in the U.S. for the treatment of patients with gastric cancer, including gastroesophageal junction cancer.

Clinical Laserthermia Systems AB announced it is conducting new in-vivo precision laser ablation treatment studies for neuro and prostate using its TRANBERG Thermal Therapy System with Thermoguide thermometry software.

Diversigen, Inc., a subsidiary of OraSure Technologies Inc., and Nom Nom™, a direct-to-consumer pet health brand, announced that Nom Nom has selected Diversigen as their preferred provider for metagenomics and microbiome sequencing and analysis services.

Cardinal Health announced that it is sending an irrevocable notice of early redemption to the holders of the Company’s $500 million 4.625% notes due 2020.

Solid Biosciences Inc. announced that, due to the public health impact of the novel coronavirus outbreak and governmental restrictions limiting the number of people who may gather together, its 2020 Annual Meeting of Stockholders, to be held on Tuesday, June 16, 2020 at 8:00 a.m.

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido will present a company overview at the Jefferies Virtual Healthcare Conference. The presentation will take place on Tuesday June 2, 2020 at 4:30PM ET. This meeting is being held virtually, and a live we

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Michael H. Peters , Ph.D., has joined the company’s Scientific Advisory Board. Dr. Peters is the inventor of Hoth’s newly licensed Novel Peptide COVID-19 Therapeutic, to prevent spike protein binding, which may be a leading cause of COVID-19, and could

Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it will host the Company’s 2020 Annual Meeting of Stockholders (the “Annual Meeting”) virtually due to public health concerns resulting from the coronavirus (“COVID-19”) outbreak, and government-recommended and required limits on public gatherings. Holding the meeting online will also protect the health and sa

SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announced that it will hold its 2020 Annual Meeting of Stockholders (the “Annual Meeting”) virtually due to the public health impact of the coronavirus (COVID-19) pandemic and to prioritize the health and well-being of meetin

Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of Phase 1 clinical data for its lead immuno-oncology candidate, bempegaldesleukin (BEMPEG: NKTR-214) in combination with nivolumab, in Cancer Discovery, a journal of the American Association for Cancer Research. Previously published Phase 1 data in Cancer Discovery o